Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

Endothelin Receptor B Antibodies

Close filters
No results were found for the filter!
NEW
Agonist-induced Serine435/Serine436 phosphorylation of the Endothelin Receptor B
pS435/pS436-ETB (phospho-Endothelin Receptor B...
Serine435/Serine436 (S435/S436) is major phosphorylation site of the Endothelin Receptor B (ETB). The pS435/pS436-ETB antibody detects phosphorylation in response to agonists. S435/S436 phosphorylation is likely to be involved in...
$ 375.00 *
Details
NEW
Indentification of the Endothelin Receptor B in mouse tissues.
ETB (non-phospho-Endothelin Receptor B Antibody)
The non-phospho-ETB receptor antibody is directed against the distal part of the carboxyl-terminal tail of human Endothelin Receptor B (ETB). It can be used to detect total ETB receptors in Western blots independent of phosphorylation....
$ 375.00 *
Details

The endothelin type A receptor (ETₐ), encoded by EDNRA, is a class A G protein-coupled receptor with higher affinity for endothelin-1 and endothelin-2 than for endothelin-3. It signals predominantly through Gq/11, activating phospholipase C and increasing intracellular calcium, and can also engage G12/13–RhoA signaling. ETₐ is expressed predominantly in vascular smooth muscle and is also found in cardiomyocytes, fibroblasts, and several other cell types. In vascular smooth muscle, endothelin-1 activation of ETₐ produces potent, sustained vasoconstriction. Persistent ETₐ signaling can promote cell proliferation, fibrosis, and vascular remodeling. Agonist exposure can induce receptor phosphorylation, β-arrestin recruitment, and internalization, after which ETₐ can recycle to the plasma membrane. The selective ETₐ antagonist ambrisentan is used clinically to treat pulmonary arterial hypertension. Atrasentan, another selective ETₐ antagonist, is approved in the United States to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. ETB activity is regulated by phosphorylation of carboxyl-terminal serine435/serine436 (pS435/pS436-ETB). This nomenclature refers to the human ETB receptor. This phosphorylation motif is highly conserved and is identical in mice, rats and humans. For more information on ETB pharmacology please refer to the IUPHAR database. For further reading refer to:

Barton M, Yanagisawa M. Endothelin: 30 Years From Discovery to Therapy. Hypertension. 2019 Dec;74(6):1232-1265. doi: 10.1161/HYPERTENSIONAHA.119.12105.Epub 2019 Nov 4. PMID: 31679425.

Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. Pharmacol Rev. 2016 Apr;68(2):357-418. doi: 10.1124/pr.115.011833. PMID: 26956245; PMCID: PMC4815360.

Davenport AP, D'Orléans-Juste P, Godfraind T, Maguire JJ, Ohlstein EH, Ruffolo RR. Endothelin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4).

The endothelin type A receptor (ETₐ), encoded by EDNRA , is a class A G protein-coupled receptor with higher affinity for endothelin-1 and endothelin-2 than for endothelin-3. It signals... read more »
Close window
Endothelin Receptor B Antibodies

The endothelin type A receptor (ETₐ), encoded by EDNRA, is a class A G protein-coupled receptor with higher affinity for endothelin-1 and endothelin-2 than for endothelin-3. It signals predominantly through Gq/11, activating phospholipase C and increasing intracellular calcium, and can also engage G12/13–RhoA signaling. ETₐ is expressed predominantly in vascular smooth muscle and is also found in cardiomyocytes, fibroblasts, and several other cell types. In vascular smooth muscle, endothelin-1 activation of ETₐ produces potent, sustained vasoconstriction. Persistent ETₐ signaling can promote cell proliferation, fibrosis, and vascular remodeling. Agonist exposure can induce receptor phosphorylation, β-arrestin recruitment, and internalization, after which ETₐ can recycle to the plasma membrane. The selective ETₐ antagonist ambrisentan is used clinically to treat pulmonary arterial hypertension. Atrasentan, another selective ETₐ antagonist, is approved in the United States to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. ETB activity is regulated by phosphorylation of carboxyl-terminal serine435/serine436 (pS435/pS436-ETB). This nomenclature refers to the human ETB receptor. This phosphorylation motif is highly conserved and is identical in mice, rats and humans. For more information on ETB pharmacology please refer to the IUPHAR database. For further reading refer to:

Barton M, Yanagisawa M. Endothelin: 30 Years From Discovery to Therapy. Hypertension. 2019 Dec;74(6):1232-1265. doi: 10.1161/HYPERTENSIONAHA.119.12105.Epub 2019 Nov 4. PMID: 31679425.

Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. Pharmacol Rev. 2016 Apr;68(2):357-418. doi: 10.1124/pr.115.011833. PMID: 26956245; PMCID: PMC4815360.

Davenport AP, D'Orléans-Juste P, Godfraind T, Maguire JJ, Ohlstein EH, Ruffolo RR. Endothelin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4).

Recently viewed